Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 7, 2007, Pages 829-837

  Vazquez Roque, Maria I ^a   Camilleri, Michael ^a   Clark, Matthew M ^b   TePoel, Debra A ^a   Jensen, Michael D ^b   Graszer, Karen M ^b   Kalsy, Sarah A ^b   Burton, Duane D ^a   Baxter, Kari L ^a   Zinsmeister, Alan R ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; GASTROINTESTINAL HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; NEUROTRANSMITTER TRANSPORTER; NORADRENALIN; PEPTIDE YY; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PLACEBO; SEROTONIN; SEROTONIN RECEPTOR; SIBUTRAMINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; MALE; OBESITY; PROMOTER REGION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH EMPTYING; STOMACH FUNCTION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; APPETITE DEPRESSANTS; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOBUTANES; DNA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GASTRIC EMPTYING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OBESITY; ORGAN SIZE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; STOMACH; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 34447095717     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.02.037     Document Type: Article

References (44)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Yanovski S.Z., and Yanovski J.A. Obesity. N Engl J Med 346 (2002) 591-602
3. Arterburn D.E., Crane P.K., and Veenstra D.L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164 (2004) 994-1003
4. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
5. Meguid M.M., Fetissov S.O., Varma M., et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 16 (2000) 843-857
6. Weintraub M., Sundaresan P.R., Madan M., et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51 (1992) 586-594
7. Weintraub M., Sundaresan P.R., Schuster B., et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther 51 (1992) 608-614
8. Deutsch J.A., Young W.G., and Kalogeris T.J. The stomach signals satiety. Science 201 (1978) 165-167
9. Deutsch J.A. The role of the stomach in eating. Am J Clin Nutr 42 (1985) 1040-1043
10. Thumshirn M., Camilleri M., Choi M.G., et al. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 116 (1999) 573-585
11. Tack J., and Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut 51 (2002) i77-i80
12. Peters W.R., MacMurry J.P., Walker J., et al. Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women. Obes Res 11 (2003) 415-419
13. 3) C825T polymorphism. Pharmacogenetics 13 (2003) 453-459
14. Kim H.J., Camilleri M., Carlson P.J., et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 53 (2004) 829-837
15. Yeo A., Boyd P., Lumsden S., et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 53 (2004) 1452-1458
16. Camarena B., Ruvinskis E., Santiago H., et al. Serotonin transporter gene and obese females with impulsivity. Mol Psychiatry 7 (2002) 829-830
17. Yamakawa M., Fukushima A., Sakuma K., et al. Serotonin transporter polymorphisms affect human blood glucose control. Biochem Biophys Res Commun 334 (2005) 1165-1171
18. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
19. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
20. Swenson W.M., and Morse R.M. The use of a self-administered alcoholism screening test (SAAST) in a medical center. Mayo Clin Proc 50 (1975) 204-208
21. Yanovski S.Z. Binge eating disorder: current knowledge and future directions. Obes Res 1 (1993) 306-324
22. Bouras E.P., Delgado-Aros S., Camilleri M., et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 51 (2002) 781-786
23. Delgado-Aros S., Burton D., Brinkmann B.H., et al. Reliability of a semi automated analysis to measure gastric accommodation using SPECT in humans. Gastroenterology 120 (2001) A-287
24. De Schepper H., Camilleri M., Cremonini F., et al. Comparison of gastric volumes in response to isocaloric liquid and mixed meals in humans. Neurogastroenterol Motil 16 (2004) 567-573
25. Camilleri M., Zinsmeister A.R., Greydanus M.P., et al. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 36 (1991) 609-615
26. Tack J., Piessevaux H., Coulie B., et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115 (1998) 1346-1352
27. Delgado-Aros S., Cremonini F., Castillo J.E., et al. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology 126 (2004) 432-440
28. Jensen M.D., Kanaley J.A., Roust L.R., et al. Assessment of body composition with use of dual-energy x-ray absorptiometry: evaluation and comparison with other methods. Mayo Clin Proc 68 (1993) 867-873
29. 3 C825T genotype and lower functional gastrointestinal disorders?. Gastroenterology 130 (2006) 1985-1994
30. Camilleri M., Atanasova E., Carlson P.J., et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123 (2002) 425-432
31. Brownell K. The LEARN program for weight management. 10th ed. (2004), American Health Publishing Company, Dallas, TX
32. Xu J., and Chen J.D. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity 14 (2006) 1363-1370
33. Kim E.J., Park E.K., and Suh K.H. Safety pharmacology of sibutramine mesylate, an anti-obesity drug. Hum Exp Toxicol 24 (2005) 109-119
34. Delgado-Aros S., Camilleri M., Cremonini F., et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 127 (2004) 1685-1694
35. Delgado-Aros S., Camilleri M., Castillo E.J., et al. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol 3 (2005) 997-1006
36. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
37. Zhang T., Brubaker P.L., Thompson J.C., et al. Characterization of peptide-YY release in response to intracolonic infusion of amino acids. Endocrinology 132 (1993) 553-557
38. Brechet S., Plaisancie P., Dumoulin V., et al. Involvement of beta1- and beta2- but not beta3-adrenoceptor activation in adrenergic PYY secretion from the isolated colon. J Endocrinol 168 (2001) 177-183
39. Lin H.C., Neevel C., and Chen J.H. Slowing intestinal transit by PYY depends on serotonergic and opioid pathways. Am J Physiol 286 (2004) G558-G563
40. Lin H.C., Neevel C., Chen P.S., et al. Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway. Am J Physiol 285 (2003) G1310-G1316
41. Batterham R.L., Cohen M.A., Ellis S.M., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
42. Spiller R.C., Trotman I.F., Adrian T.E., et al. Further characterisation of the 'ileal brake' reflex in man-effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 29 (1988) 1042-1051
43. Yajima H., Komatsu M., Sato Y., et al. Norepinephrine inhibits glucose-stimulated, Ca2+-independent insulin release independently from its action on adenylyl cyclase. Endocr J 48 (2001) 647-654
44. 3) C825T polymorphism. Pharmacogenetics 13 (2003) 453-459